Difference between revisions of "Non-small cell lung cancer, HER2-mutated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''") |
||
| Line 60: | Line 60: | ||
===References=== | ===References=== | ||
| − | #'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains | + | #'''DESTINY-Lung01:''' Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. [https://doi.org/10.1056/nejmoa2112431 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/34534430/ PubMed] NCT03505710 |
#'''DESTINY-Lung02:''' NCT04644237 | #'''DESTINY-Lung02:''' NCT04644237 | ||
Revision as of 12:51, 29 August 2022
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Metastatic disease, all lines of therapy
Trastuzumab deruxtecan monotherapy
Regimen variant #1, 5.4 mg/kg
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 (RT) |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 5.4 mg/kg IV once on day 1
21-day cycles
Regimen variant #2, 6.4 mg/kg
| Study | Years of enrollment | Evidence |
|---|---|---|
| Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
| Awaiting publication (DESTINY-Lung02) | 2021-ongoing | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251. Epub 2021 Sep 18. link to original article contains dosing details in manuscript PubMed NCT03505710
- DESTINY-Lung02: NCT04644237